These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15011585)

  • 1. [Potent new protease inhibitor. Boostered protease inhibitors--a separate class of drugs].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():40-1. PubMed ID: 15011585
    [No Abstract]   [Full Text] [Related]  

  • 2. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 3. [No selection of mutations. 908 raises genetic resistance barrier].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():41. PubMed ID: 15011586
    [No Abstract]   [Full Text] [Related]  

  • 4. Lower dose of ritonavir approved for use with fosamprenavir.
    Sax PE
    AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F;
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency.
    Torres HA; Barnett BJ; Arduino RC
    Clin Infect Dis; 2007 Mar; 44(6):887-8. PubMed ID: 17304468
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA approves new dosing for amprenavir and ritonavir combination.
    AIDS Treat News; 2002 Mar; (378):6-7. PubMed ID: 11965920
    [No Abstract]   [Full Text] [Related]  

  • 9. Four posters add to our knowledge of Lexiva.
    Proj Inf Perspect; 2008 Dec; (47):7-8. PubMed ID: 19227558
    [No Abstract]   [Full Text] [Related]  

  • 10. [Maintaining independence. New protease inhibitor receives drug approval recommendation].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():84-5. PubMed ID: 15373062
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long-term virus suppression. Expanding therapy options with protease inhibitor].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():68-9. PubMed ID: 16385882
    [No Abstract]   [Full Text] [Related]  

  • 12. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
    Kurowski M; Walli RK; Breske A; Kruse G; Stocker H; Banik N; Richter H; Mazur D
    AIDS; 2007 Jun; 21(10):1368-70. PubMed ID: 17545717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M; Clay PG; Anderson PL; Glaros AG
    Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New formulation--fewer tablets--optimal effect].
    Krankenpfl J; 2005; 43(7-10):249. PubMed ID: 16515318
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA grants approval to fosamprenavir calcium.
    AIDS Alert; 2004 Jan; 19(1):11-2. PubMed ID: 14974421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA; Arduino RC
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA approves Lexiva.
    IAPAC Mon; 2003 Nov; 9(11):280. PubMed ID: 14989187
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA notifications. FDA approves new formulation of Lexiva.
    AIDS Alert; 2007 Aug; 22(8):90-1. PubMed ID: 17768778
    [No Abstract]   [Full Text] [Related]  

  • 20. New dosing regimen approved.
    AIDS Patient Care STDS; 2002 Apr; 16(4):190. PubMed ID: 12015873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.